Advertisement
Advertisement
U.S. Markets open in 3 hrs 5 mins
Advertisement
Advertisement
Advertisement
Advertisement

Navidea Biopharmaceuticals, Inc. (NAVB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.2000-0.0300 (-2.44%)
At close: 04:00PM EST
1.3000 +0.10 (+8.33%)
After hours: 07:45PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2300
Open1.2400
Bid0.0000 x 3000
Ask0.0000 x 1000
Day's Range1.2000 - 1.3200
52 Week Range1.2000 - 3.1500
Volume43,717
Avg. Volume59,924
Market Cap34.83M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.4520
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • Zacks

    Will Navidea Biopharma (NAVB) Report Negative Q3 Earnings? What You Should Know

    Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

    DUBLIN, Ohio, November 03, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, November 10, 2021 at 5:00 p.m. (EST) to discuss financial results and corporate developments for the third quarter ended September 30, 2021.

  • Business Wire

    Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

    DUBLIN, Ohio, October 26, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021. Mr. Latkin and the Company are discussing the terms of

Advertisement
Advertisement